U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H5O6.Na
Molecular Weight 172.0687
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM BITARTRATE

SMILES

[Na+].O[C@H]([C@@H](O)C([O-])=O)C(O)=O

InChI

InChIKey=NKAAEMMYHLFEFN-ZVGUSBNCSA-M
InChI=1S/C4H6O6.Na/c5-1(3(7)8)2(6)4(9)10;/h1-2,5-6H,(H,7,8)(H,9,10);/q;+1/p-1/t1-,2-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C4H5O6
Molecular Weight 149.0789
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tartaric acid is found in many plants such as grapes, tamarinds, pineapples, mulberries and so on. Wine lees (called mud in the US), the sediment collected during the fermentation of grapes, contains potassium bitartrate (potassium hydrogen tartrate) as its major component. L-(+)-tartaric acid is an enantiomer of tartaric acid. Twenty five years before the tetrahedral structure for carbon was proposed in 1874 to explain the optical activity and other properties of organic compounds, Louis Pasteur discovered the existence of enantiomerism in tartaric acid. L-(+)-tartaric acid is widely used in food and beverage as acidity regulator with E number E334.

Originator

Curator's Comment: Scheele first prepared tartaric acid. Louis Pasteur discovered the existence of enantiomerism in tartaric acid

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Inactive ingredient
CLEARASIL DAILY CLEAR CLEAR SKIN

Approved Use

Unknown
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no
yes [Ki 91 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator.
2002-10-25
Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5.
2002-10-15
Synovial macrophage-osteoclast differentiation in inflammatory arthritis.
2002-10
Ectonucleotide diphosphohydrolase activity in Crithidia deanei.
2002-10
Formation of methylantimony species by an aerobic prokaryote: Flavobacterium sp.
2002-10
Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors.
2002-10
Symmetric and helical growth of polyacetylene fibers over a single copper crystal derived from copper tartrate decomposition.
2002-09-05
Towards atomic resolution with crystals grown in gel: the case of thaumatin seen at room temperature.
2002-08-01
Boronic acid receptors for alpha-hydroxycarboxylates: high affinity of Shinkai's glucose receptor for tartrate.
2002-07-26
Engineering the substrate specificity of D-amino-acid oxidase.
2002-07-26
High frequency of phenotypic deviations in Physcomitrella patens plants transformed with a gene-disruption library.
2002-07-18
Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers.
2002-07-18
A simple spectrophotometric method for the determination of copper in industrial, environmental, biological and soil samples using 2,5-dimercapto-1,3,4-thiadiazole.
2002-07
Stereoselective radical reactions of some tartaric and glyceric acid derivatives.
2002-06-13
Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo.
2002-06-07
Determination of the side-products formed during the nitroxide-mediated bleach oxidation of glucose to glucaric acid.
2002-06-05
The separation of racemic crystals into enantiomers by chiral block copolymers.
2002-06-03
Effects of cyclic pressure on bone marrow cell cultures.
2002-06
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice.
2002-06
Release of an acid phosphatase activity during lily pollen tube growth involves components of the secretory pathway.
2002-05
Use of disposable GRC electrodes for the detection of phenol and chlorophenols in liquid chromatography.
2002-05
Crystallization and preliminary X-ray crystallographic analysis of UDP-N-acetylglucosamine acyltransferase from Helicobacter pylori.
2002-05
Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells.
2002-05
Stereoselective synthesis of myo-inositol via ring-closing metathesis: a building block for glycosylphosphatidylinositol (GPI) anchor synthesis.
2002-04-18
Effect of antibiotics on in vitro and in vivo avian cartilage degradation.
2002-04-02
In vitro antibiotic susceptibility of field isolates of Mycoplasma synoviae in Argentina.
2002-04-02
The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
2002-04
New materials for ESR dosimetry.
2002-04
Acid phosphatases.
2002-04
The structure and mechanism of the type II dehydroquinase from Streptomyces coelicolor.
2002-04
Initial stages of cell-matrix adhesion can be mediated and modulated by cell-surface hyaluronan.
2002-04
Chiral versus racemic building blocks in supramolecular chemistry: tartrate salts of organic diamines.
2002-04
Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.
2002-03-18
Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice.
2002-03-01
Gender- and age-related differences in osteoclast formation from circulating precursors.
2002-03
Screening method for inherited disorders of purine and pyrimidine metabolism by capillary electrophoresis with reversed electroosmotic flow.
2002-02-15
Thermophysical properties of pharmaceutically compatible buffers at sub-zero temperatures: implications for freeze-drying.
2002-02
Retention of anions on silica-based metalloporphyrin stationary phases.
2002-02
Ergotamine-induced anorectal strictures: report of five cases.
2002-02
Diaquabis[mu-(R,R)-tartrato-kappa4O1,O2:O3,O4]dinickel(II) trihydrate.
2002-02
The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter.
2002-02
Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells.
2002-02
From local adsorption stresses to chiral surfaces: (R,R)-tartaric acid on Ni(110).
2002-01-23
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
2002-01
Therapy and disease concepts: the history (and future?) of antimony in cancer.
2002-01
Some comparative aspects of the pharmacokinetics of tylosin in buffaloes and cattle.
2002-01
Anaerobaculum mobile sp. nov., a novel anaerobic, moderately thermophilic, peptide-fermenting bacterium that uses crotonate as an electron acceptor, and emended description of the genus Anaerobaculum.
2002-01
Preformulation studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability.
2002
[Acid phosphatase, ACP (EC 3.1.3.2)].
2001-11
Cell-surface recognition of biotinylated membrane proteins requires very long spacer arms: an example from glucose-transporter probes.
2001-01-08
Patents

Sample Use Guides

L-( )-tartaric acid as a food additive. Acceptable Daily Intake: 0-30 mg/kg
Route of Administration: Oral
In Vitro Use Guide
After incubation in medium containing 50 mM L( )-tartaric acid, osteoclasts and chondroclasts were heavily stained with reaction product.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:05 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:05 GMT 2025
Record UNII
75E63I9H07
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
E-335(I)
Preferred Name English
SODIUM BITARTRATE
II   MART.   MI   WHO-DD  
Systematic Name English
SODIUM BITARTRATE [MART.]
Common Name English
INS-335(I)
Code English
MONOBASIC SODIUM TARTRATE
Common Name English
SODIUM HYDROGEN L-TARTRATE
Systematic Name English
Sodium bitartrate [WHO-DD]
Common Name English
MONOSODIUM TARTRATE
Systematic Name English
SODIUM BITARTRATE [II]
Common Name English
BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, MONOSODIUM SALT
Common Name English
INS NO.335(I)
Code English
MONOSODIUM L-(+)-TARTRATE
Systematic Name English
MONOSODIUM DL-TARTRATE
Common Name English
TARTARIC ACID, MONOSODIUM SALT
Common Name English
SODIUM BITARTRATE [MI]
Common Name English
SODIUM ACID TARTRATE
Common Name English
BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, SODIUM SALT (1:1)
Common Name English
SODIUM HYDROGEN TARTRATE
Systematic Name English
Classification Tree Code System Code
JECFA EVALUATION INS-335(I)
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
CFR 21 CFR 331.11
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-335(I)
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
CFR 21 CFR 331.15
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
Code System Code Type Description
CAS
526-94-3
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
FDA UNII
75E63I9H07
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
SMS_ID
100000078102
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
EPA CompTox
DTXSID70883423
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
WIKIPEDIA
MONOSODIUM TARTRATE
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-400-9
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
MERCK INDEX
m9995
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY Merck Index
PUBCHEM
23684900
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
EVMPD
SUB15273MIG
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY
RXCUI
89900
Created by admin on Mon Mar 31 17:36:05 GMT 2025 , Edited by admin on Mon Mar 31 17:36:05 GMT 2025
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS